Target intelligence / Profile preview

Influenza A Hemagglutinin Protein H3N2 Subtype (HA H3N2)

Target
HA H3N2
Molecular classification
Viral surface glycoprotein, Hemagglutinin
01

Overview

The hemagglutinin (HA) protein is a surface glycoprotein of the influenza A virus, essential for viral entry into host cells. The H3N2 subtype refers to one of the major human-infecting forms, first emerging in 1968 and responsible for significant seasonal influenza outbreaks. HA binds sialic acid-containing receptors on respiratory epithelial cells, determining species specificity and initiating infection. After endocytosis into host cells, acidic pH triggers conformational changes in HA that expose its fusion peptide, allowing viral and cellular membranes to merge—releasing viral RNA into the cytoplasm for replication. H3N2 has circulated in humans since 1968 and undergoes frequent antigenic drift, mutations that allow escape from immune recognition while maintaining function. Major antigenic sites overlap with or surround the receptor-binding site on HA1, leading to continual changes requiring regular updates to seasonal vaccines targeting this protein.

Other names
H3N2 HemagglutininHAHemagglutininH3 Hemagglutinin
02

Mechanism of action

Neutralization of HA through antibody binding; Inhibition of receptor binding; Prevention of membrane fusion

03

Biological functions

Receptor bindingMembrane fusionViral entryAntigen presentation
04

Disease associations

InfectionInfluenzaRespiratory disease
05

Safety considerations

Antigenic drift leading to vaccine mismatchPotential for antibody-dependent enhancement (ADE) of infection
06

Interacting drugs

NA inhibitors (e.g., Oseltamivir, Zanamivir) - indirectly by preventing viral release

2 more in the full profile.

07

Biomarkers

HA antibody titers (vaccine efficacy)HA sequence (strain identification, antigenic drift monitoring)

Beyond the preview

Go deeper on Influenza A Hemagglutinin Protein H3N2 Subtype (HA H3N2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Influenza A Hemagglutinin Protein H3N2 Subtype (HA H3N2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call